Pulmonary Fibrosis
6 videos · updated daily
1:29 LTI-03 Phase 1b Data Published in Nature Communications
Rein Therapeutics CSO Cory Hogaboam on published Phase 1b data for inhaled LTI-03 in idiopathic pulmonary fibrosis, and how they inform the ongoing Phase 2 RENEW trial.
1:50 Rein Therapeutics on LTI-03 in IPF
Cory Hogaboam, Chief Scientific Officer of Rein Therapeutics, explains how preserving lung function informs development of inhaled LTI-03, which in October 2026 was being evaluated in the Phase 2 RENEW trial in idiopathic pulmonary fibrosis.
1:06 Inhaled Treprostinil in IPF: The TETON-2 Trial
Dr. Glaucomflecken summarizes for NEJM Group the TETON-2 trial, which examined whether inhaled treprostinil could improve outcomes in patients with idiopathic pulmonary fibrosis.
1:29 LTI-03 and the Phase 2 RENEW Trial in IPF
Brian Windsor, Ph.D., President and CEO of Rein Therapeutics, explains why approved IPF drugs only slow the disease and describes LTI-03, an inhaled peptide that in September 2026 was being evaluated in the Phase 2 RENEW trial.
1:55 REIN Update- Ramping up Phase 2 Trial and Completed $50 Million Financing
Rein Therapeutics CEO Brian Windsor on where the Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis stands, and on a completed $50 million raise.
9:33 Rentosertib: From AI-Discovered Target to Phase 3
Insilico Medicine traces rentosertib, a TNIK inhibitor designed with AI for fibrosis, from target discovery through Phase 2a to Phase 3, where it was in September 2026, and an analysis applying six proteomic aging clocks to Phase 2a trial data.